LIXTE Biotechnology Provides Update On Recent Activities And Developments; Collaboration With NKI And Funding Support For New Colorectal Cancer Clinical Trial By Major Pharma Co; Preclinical Data Published In Journal EMBO Reports Shows LB-100 As...
LIXTE Biotechnology Provides Update On Recent Activities And Developments; Collaboration With NKI And Funding Support For New Colorectal Cancer Clinical Trial By Major Pharma Co; Preclinical Data Published In Journal EMBO Reports Shows LB-100 As...
LIXTE Biotechnology Provides Update On Recent Activities And Developments; Collaboration With NKI And Funding Support For New Colorectal Cancer Clinical Trial By Major Pharma Co; Preclinical Data Published In Journal EMBO Reports Shows LB-100 As Potentially Enhancing The Benefit Of Immunotherapy
LIXTE Biotechnology關於最新活動和進展的更新；與NKI的合作以及大型藥品公司對新結直腸癌臨床試驗的資助支持；發表在EMBO Reports期刊上的臨床前數據顯示Lb-100有可能增強免疫治療的效果。
-Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial by Major Pharma Company-
與NKI的合作以及大型藥品公司對新結直腸癌臨床試驗的資助支持。
-Distinguished Oncologist Jan Schellens Joins LIXTE as Chief Medical Officer-
知名腫瘤學家Jan Schellens加入LIXTE擔任首席醫務官。
-Preclinical Data Published in Journal EMBO Reports Shows LB-100 as Potentially Enhancing the Benefit of Immunotherapy-
發表在EMBO Reports期刊上的臨床前數據顯示Lb-100有可能增強免疫治療的效果。
-LIXTE to Present at Two Upcoming Investor Conferences-
LIXTE將在兩個即將舉行的投資者會議上發表演講。
PASADENA, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on the Company's recent activities.
2024年8月19日加利福尼亞州帕薩迪納（GLOBE NEWSWIRE）—LIXTE Biotechnology Holdings, Inc.（「LIXTE」或「公司」）（納斯達克代碼：LIXT）是一家臨床階段的藥品公司，開發一類新型的癌症治療，以增強化療和免疫治療的效果，今天對公司最近的活動進行了更新。
"We are encouraged by the growing interest shown by major pharmaceutical companies in our proprietary compound, LB-100, as demonstrated by their support in clinical trial collaborations," said Bas van der Baan, LIXTE's President and Chief Executive Officer.
「我們對大型藥品公司對我們的專有化合物Lb-100表現出的日益濃厚興趣感到鼓舞，這一點得到了他們在臨床試驗合作中的支持，」LIXTE的總裁兼首席執行官Bas van der Baan說道。
